Oct 29 (Reuters) – Swiss dental implant company Straumann (STMN.S) reported an 8.3% rise in third-quarter organic sales on Wednesday, slightly surpassing market expectations. The growth was driven by strong performance in North America and most Asia-Pacific markets, which offset weaker demand in China.
The company’s revenue for the July-September period reached 602.2 million Swiss francs ($759.3 million). Analysts had predicted sales of 600.6 million francs, according to a Vara consensus. Following the announcement, Straumann’s shares rose 5.8% to 92.86 francs.
Straumann said sales in the Asia-Pacific region totaled 144.3 million francs, falling short of the consensus estimate of 151.5 million francs. This region represents roughly one-quarter of the company’s total sales. The slowdown in China contributed to the gap, as patients delayed dental treatments and distributors reduced inventory ahead of the country’s next round of volume-based procurement (VBP).
“We still have to see, and we will have more information by the end of the year when the Chinese authorities publish how they will run this new VBP round for dental implants,” CEO Guillaume Daniellot told Reuters in an interview. He noted that Straumann is preparing for challenges in China over the next two quarters but remains confident about its business in other regions.
Daniellot added, “We believe that we can compensate for some of the shortfall in China based on strong results and growth in other geographies.”
In North America, sales reached 161.6 million francs, nearly matching analysts’ estimates of 159.6 million francs. The company said growth in the region was supported by commercial execution and rising demand for both premium and challenger brands.
Straumann also announced new partnerships in its orthodontics business. The company will transfer clear aligner manufacturing for Europe, the Middle East, Africa (EMEA), and Asia-Pacific to Smartee, its partner in China. The move is part of the company’s broader strategy to expand its orthodontics operations globally.
Despite challenges in China, Straumann confirmed its full-year guidance. The company continues to expect high single-digit organic revenue growth in 2025. It emphasized that growth in North America and other Asia-Pacific markets will help balance the temporary slowdown in China.
Industry analysts said Straumann’s results reflect resilience in global dental markets. Strong demand for implants and orthodontic solutions, along with strategic collaborations, are likely to support growth in 2025. However, the company will closely monitor developments in China, where regulatory changes and procurement policies could affect short-term performance.
Straumann remains a major player in the global dental implant market. Its diversified presence across regions and brands positions it to navigate market fluctuations while continuing to expand its product offerings.